Overview

Staccato Zaleplon Single Dose Pharmacokinetics

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to determine the safety, tolerability and pharmacokinetics of zaleplon delivered by the Staccato thermal aerosol system in healthy volunteers
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Treatments:
Zaleplon
Criteria
Inclusion Criteria:

- Male and female subjects between the ages of 18 to 55 years, inclusive who are in good
general health

Exclusion Criteria:

- Subjects with a history of allergy or intolerance to zaleplon. Subjects who have any
other disease or condition, by history, physical examination, or laboratory
abnormalities that in the investigator's opinion, would present undue risk to the
subject, or may confound the interpretation of study results.